Just reported
Q3 2026 results
From Orasure Technologies, Inc.'s results release of November 9, 2026; its quarterly report has since been filed.
Revenue
Actual
$30.9M
+14% y/y ↑
+0.9% q/q ↑
EPS, GAAP
Operating income, GAAP
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|
| Total Revenue | $30.9M | $27.1M | +14.11% |
| Profit | -$13.1M | -$13.7M | +4.51% |
| Profit per share | -$0.19 | -$0.19 | 0.00% |
| Free Cash Flow | -$12.5M | -$11M | -14.16% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Earnings calls
NewThe latest call
FetchingOrasure Technologies, Inc. reported on November 9, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
What management said
“Our third quarter results demonstrate the continued execution of our strategy. In addition to delivering double-digit year-over-year revenue growth, we meaningfully expanded gross margins and benefited from operational efficiency initiatives that reduced our cost base,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
How the share price reacted
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Close before
$3.44
Nov 6, 2026
Close after
$3.32
Nov 10, 2026
Move
-3.49%
0 shares traded, against a normal 605.02K
What Orasure Technologies, Inc. does
OraSure Technologies, Inc. (“OraSure” or “OTI”) transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc., Sherlock Biosciences, Inc., and BioMedomics, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physicians’ offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Orasure Technologies, Inc.’s Item 2.02 8-K filed November 9, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
